Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, COLLEGIUM PHARMACEUTICAL, INC reported revenue of $781M, up 23.6% year over year. Operating margin was 23.0% and net margin 8.1%, on a free-cash-flow margin of 42.0% with capital expenditure at 0.2% of revenue. Every figure is computed directly from COLL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $781M | 23.0% | 8.1% |
| FY2024 | $631M | 26.9% | 11.0% |
| FY2023 | $567M | 29.5% | 8.5% |
| FY2022 | $464M | 7.2% | -5.4% |
| FY2021 | $277M | 6.4% | 25.8% |
How does COLL compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.